X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Lead Product(s): Survodutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BI 456906
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
The net proceeds will be used to further strengthen Zealand’s investment in its differentiated assets targeting obesity, including BI 456906 (survodutide), a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration.
Lead Product(s): Survodutide
Therapeutic Area: Nutrition and Weight Loss Product Name: BI 456906
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Carnegie Investment Bank
Deal Size: $214.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 08, 2024
Details:
ZP1848 (glepaglutide) is a long-acting GLP-2 analog synthetic peptide, which is currently being evaluated for the treatment of patients with short bowel syndrome.
Lead Product(s): Glepaglutide
Therapeutic Area: Gastroenterology Product Name: ZP1848
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
ZP4207 (dasiglucagon) is a glucagon receptor agonist, peptide drug candidate, which is currently being evaluated for the treatment of congenital hyperinsulinism.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
BI 456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist that activates both the GLP-1 and glucagon receptors, which is investigating for the treatment of weight loss in people living with overweight or obesity.
Lead Product(s): Survodutide
Therapeutic Area: Nutrition and Weight Loss Product Name: BI 456906
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
ZP4207 (dasiglucagon) is being investigated by Zealand Pharma for subcutaneous continuous infusion using a wearable pump system as a potential treatment of congenital hyperinsulinism in pediatric patients 7 days of age and older.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
ZP8396 is an investigational, potent long-acting amylin analogue designed to improve solubility, minimize fibrillation and allow for co-formulation with other peptides, including GLP-1 analogues, it holds potential for the treatment of obesity.
Lead Product(s): ZP8396
Therapeutic Area: Nutrition and Weight Loss Product Name: ZP8396
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
ZP4207 (dasiglucagon) subcutaneous injection is a glucagon receptor agonist and indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023
Details:
Zegalogue (dasiglucagon) subcutaneous injection is a glucagon receptor agonist and indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Lead Product(s): Dasiglucagon
Therapeutic Area: Endocrinology Product Name: Zegalogue
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Boehringer Ingelheim is developing BI 456906, a novel glucagon receptor/GLP-1 receptor dual agonist, for the treatment of people living with overweight or obesity as well as for the treatment people living with of Nonalcoholic Steatohepatatis (NASH).
Lead Product(s): BI 456906
Therapeutic Area: Nutrition and Weight Loss Product Name: BI 456906
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
